Survival activating factor enhancement

New Data Supports High Reperfusion Rate for Anaconda Biomed’s Mechanical Thrombectomy System

Retrieved on: 
Wednesday, February 17, 2021
Medical devices, Health, Hospitals, Surgery, Clinical trials, General Health, Survival activating factor enhancement, Ischemia, Reperfusion injury

The results help explain the high rate of reperfusion shown in early results from the multi-center SOLONDA (SOLitaire in combination with the ANA Catheter system manufactured by AnacONDA) trial, published in December 2020 in the Journal of Neuroradiology .

Key Points: 
  • The results help explain the high rate of reperfusion shown in early results from the multi-center SOLONDA (SOLitaire in combination with the ANA Catheter system manufactured by AnacONDA) trial, published in December 2020 in the Journal of Neuroradiology .
  • The 125-patient prospective study is designed to assess system safety and reperfusion, measured using the modified treatment in cerebral infarction (mTICI) score.
  • Early results from SOLONDA showed promisingly high rates of first-pass complete reperfusion, said Dr. Marc Ribo, of the Dept.
  • Results from our in vitro study help explain those high reperfusion rates for the ANA Catheter.

The Future of Amazon: How COVID-19 has Validated the Business Model

Retrieved on: 
Tuesday, September 22, 2020
3D publishing, Amazon, Rivers, Publishing, Survival activating factor enhancement, Retailers

Currently there is a broad consensus that Amazon will emerge as one of the winners of the pandemic, however this report examines the overall picture.

Key Points: 
  • Currently there is a broad consensus that Amazon will emerge as one of the winners of the pandemic, however this report examines the overall picture.
  • It is safe to assume that shoppers will be likely to go out less even when restrictions are lifted.
  • A number of Amazon's big bets in technological innovations look much better now than just a few months ago.
  • Touch free, voice activated devices might get a huge push, as sound activation is clearly more hygienic than touch activation.

Axcella Presents Mechanistic Data Demonstrating that AXA1125 Modulated Liver Metabolic, Inflammatory and Fibrotic Pathways

Retrieved on: 
Thursday, January 24, 2019
Health, Biotechnology, Pharmaceutical, General Health, Branches of biology, Biology, Doctor of Philosophy, Titles, MTOR, Survival activating factor enhancement, Metabolism

The new data were introduced in an oral presentation by Svetlana Marukian, Ph.D., Senior Director, Discovery at Axcella.

Key Points: 
  • The new data were introduced in an oral presentation by Svetlana Marukian, Ph.D., Senior Director, Discovery at Axcella.
  • AXA1125 is a novel composition of EMMs designed to simultaneously support metabolic, inflammatory and fibrotic pathways associated with liver health.
  • These data demonstrate the ability of our platform and development paradigm to rapidly obtain a significant depth and breadth of information, said Bill Hinshaw, President and Chief Executive of Axcella.
  • In these studies, Axcella evaluates AXA Candidates for safety, tolerability, and effects on the normal structures and functions of the body.